Negative control for PF CBP1
(Cat. No. 5801). Exhibits negligible activity at CBP and BRD4.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Other Product-Specific Information:
Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities.
Chekler et al.